Drug regulator pushes for Braille labelling on medicines
The Drugs Controller General of India (DCGI) is considering these changes based on a report of a subcommittee that recommended introducing Braille labelling for drugs packaged in mono cartons and for those frequently used by the visually impaired, such as eye drops.
'Currently, there is no labelling provision in the Drugs and Cosmetics Act and Rules that considers the needs of blind or visually impaired people," the panel recommended. 'As a result, this special category of people finds it difficult to know the name and expiry date of medicines. Therefore, a provision should be made to label drugs with Braille inscriptions."
The recommendations stem from a 2020 representation highlighting the difficulties visually-impaired individuals faced when trying to read medicine strips. The subcommittee was first constituted in 2020 and then reconstituted in October 2024 under KR Chawal, Drug Controller and Licensing Authority of Delhi, along with three more members.
Also read: Which private hospital is best for you? New grading system will help patients decide on treatment options
An added benefit
The committee report also said that Braille labelling will help combat counterfeit drugs. 'Braille fonts on drug pack labels are unique and difficult to copy, which could significantly reduce the incidence of drug duplication and spurious products in the market," according to the documents of the 66th Drugs Consultative Meeting (DCC) reviewed by Mint.
India's spurious or counterfeit medicine drug sales are valued at $3 billion. The country's overall medicine market is currently valued at $50 billion, with domestic consumption at $23.5 billion, according to the department of pharmaceuticals.
Queries emailed to the spokespersons of the health and family ministry and the DCGI remained unanswered till press time.
Voluntary rollout, initially
The subcommittee's recommendations presented to the Drugs Consultative Committee (DCC) on 17 June are currently under consideration to make the implementation voluntary or mandatory to start with through legislative amendments to the Drug Rules, 1945," said the official aware of the matter, requesting anonymity.
"Initially, it has been proposed on a voluntary basis because people (drug makers) would take time to switch over to Braille labelling. We also have to see how the Indian industry is going to adapt to change. That is why it is being proposed for additional labelling in Braille language to be implemented 'initially on a voluntary basis' for drugs supplied in mono carton pack sizes," the official said.
To ensure the accuracy of Braille labels, the subcommittee's report has recommended that drug manufacturers have their Braille artwork validated by nodal agencies such as the National Institute for the Empowerment of Persons with Intellectual Disabilities (NIEPID) through the Braille Council of India (BCI) or other NIEPID-recommended bodies.
Also read: Centre moves to enhance organ transplant services in govt hospitals after review shows capacity constraints
The report has excluded Braille labelling for medicines and other pharmaceutical items dispensed under direct healthcare professional supervision, including injectables and vaccines. Also, the report recommends that the competent authority issue an advisory to retailers, instructing them to verbally guide visually impaired customers about medicine names, dosage, indications, uses, and expiry dates. This guidance would be routinely monitored by enforcement officers.
'Putting Braille labelling on drug making is a good idea. Even if a 1% population gets benefits, it's worth doing, especially for life-saving drugs which are of significant use, and not just limiting it to certain eye drops," said Dr. J.S. Titiyal, head of Dr. Aggarwal's Eye Institute in New Delhi and former chief of RP Eye Centre at the All India Institute of Medical Sciences. He said that visually impaired individuals may have other health complications beyond eye issues.
Dr. Manipal S. Sachdeva, chairman and managing director at Centre for Sight, said Braille labelling should be on all kinds of important life-saving medicines, not just eye drops. But he expressed reservations about making it a voluntary requirement.
'We don't know how the voluntary initiative will be picked up by the manufacturers, because it will add to their expense and logistic issues."
Also read: Centre orders thorough safety review of painkiller Nimesulide for adults
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
a day ago
- Mint
Apollo Hospitals eyes medical tourism boost, capacity growth in FY26
Apollo Hospitals Enterprise Ltd (Ahel) is stepping up its medical tourism strategy, aiming to diversify its overseas patient base beyond Bangladesh, where inflows have slowed due to an ongoing economic crisis. The company's Q1FY26 results, announced on Tuesday, showed a 42% year-on-year rise in consolidated net profit to ₹ 433 crore, up from ₹ 305 crore a year earlier. Revenue from operations climbed 15% to ₹ 5,842 crore, while earnings before interest, tax, depreciation and amortization (Ebitda) rose 26% to ₹ 852 crore. The main healthcare services division delivered an 11% revenue increase to ₹ 2,935 crore, supported by high-end surgeries and growth in speciality areas such as cardiac, oncology, neurology, gastroenterology and orthopaedics. However, a 1.5% revenue hit came from reduced medical tourism from Bangladesh, which has been declining since Q3FY25. The healthcare player is looking at attracting more patients from other markets now. 'We are doing a lot to see how we can more actively engage in some of these markets,' Madhu Sasidhar, president and chief executive officer of the hospitals division, told Mint. Apollo is eyeing a larger chunk in the African-Middle East cluster, where they have already substantially increased revenues, Sasidhar said. The hospital chain is also looking at markets in the eastern corridor like Myanmar and Cambodia, Southeast Asia, and the CIS countries as well. 'Over the next few months, you will start to see some of that come to fruition,' Sasidhar added. The hospital chain is also looking at operationalizing six new hospitals, with a total of over 1,500 new beds this year. 'There is a significant capacity that will get augmented in the next one year,' chief financial officer Krishnan Akhileswaran said. The group reiterated plans to add more than 4,300 beds over the next five years and reported network occupancy at 65% versus 68% a year earlier. The company's digital pharmacy business Apollo 24/7 is on track to break even by Q4FY26, Akhileswaran said. During the first quarter of FY26, Ahel announced the demerger of its omnichannel pharmacy and digital health business into a new entity, Apollo Healthtech, which will be listed in the next 12-18 months. 'This is the appropriate time because if you look at it, by the time we demerge, it will be Q4FY27…by that time, we should be doing reasonably good margins. And with this growth, we hope that by Q4FY27, this would be a ₹ 25,000 crore run rate company, which is a sizable number for someone like us to be able to list that company,' he said. The overall digital health and omnichannel pharmacy distribution business reported a 19% YoY growth in revenues to ₹ 2,472 crore. Ebitda stood at ₹ 94 crore against ₹ 23 crore in Q1FY25, with margins at 3.8%. Net profit stood at ₹ 57 crore during the fiscal. Apollo Hospitals' shares ended 0.1% lower at ₹ 7,253 on the National Stock Exchange ahead of the results.
Mint
a day ago
- Mint
Mint Explainer: Why are private hospitals resisting the government's health insurance scheme Ayushman Bharat
Seven years after its launch, Ayushman Bharat, the government's health insurance scheme for the poor, has run into trouble. More than 600 private hospitals in Haryana suspended services for patients under the scheme this month, citing pending dues. Private and public hospitals across the country have been struggling to recover dues from the government for Ayushman Bharat patients they treat. What's going wrong? Mint explains. What is Ayushman Bharat? Also called the Ayushman Bharat Pradhan Mantri Jan Arogya Yojna (PMJAY), this health insurance scheme was launched in 2018 for India's poorest and most vulnerable people. Each family covered under the scheme gets up to ₹5 lakh cashless health insurance coverage every year. This covers secondary and tertiary care in both public and private hospitals empanelled under the scheme. Since its launch, Ayushman Bharat has issued over 41 crore cards for beneficiaries and authorised hospital admissions worth nearly ₹1.2 trillion in more than 32,000 empanelled hospitals, per latest data from the National Health Authority. How does the scheme work? Families identified at the bottom of the ranks based on deprivation occupational criteria of the Socio-Economic Caste Census 2011 qualify for the scheme, with different qualifiers for rural and urban families. Families covered under previous health insurance schemes run by the Centre and various state governments were also included in Ayushman Bharat when it launched in 2018. Patients with an Ayushman Bharat card can be treated at an empanelled hospital for free. These hospitals claim the cost of treatment from the state or central health authorities per a rate list fixed by the government under the scheme. What is the problem now? Earlier this month, over 600 private hospitals in Haryana stopped accepting patients covered by the Ayushman Bharat Scheme after more than six months of threatening to do so. These hospitals, represented by the Haryana chapter of the Indian Medical Association, said they had not been paid for the free treatments provided to government-insured patients. In a post on X (formerly Twitter), the IMA Haryana said that the Haryana government had cleared only ₹245 crore of the total pending dues worth nearly ₹500 crore as of 7 August. So, is this a Haryana-only problem? No. Private and public hospitals around the country have struggled to recover dues from the government for Ayushman Bharat patients they treat. Three years ago, Chandigarh's prestigious government-run PGI Hospital stopped treatment under Ayushman Bharat after the Punjab government failed to clear dues worth ₹16 crore. Last year, the Nursing House Cell under the IMA suspended cashless treatment for Ayushman Bharat patients in the private hospitals and nursing homes it represents, citing pending dues. Private hospitals in several other states, including Andhra Pradesh and Telangana, have been reluctant to join Ayushman Bharat; last November, a Karnataka MP even suggested 'taking action' against private hospitals that refuse to be enrolled in the scheme. How much are hospitals across India owed under the Ayushman Bharat scheme? The National Health Authority has not officially disclosed this figure on its dashboard for the scheme. However, in a reply to a Right to Information query by activist Ajay Basudev Bose, it said that empanelled hospitals were owed over ₹1.21 trillion in unpaid dues as of February this year. The health ministry did not respond to a Mint query regarding pending dues. In 2023, the minister of state in the health ministry said in a Lok Sabha reply that 77% of all claims were settled under the Ayushman Bharat scheme overall, and 86% of all claims made in private hospitals, as of February that year. What happens now? The Centre and various state governments must settle pending dues or issue a formal rejection of claims for cases pending with empanelled hospitals. Bose's RTI query cited above said nearly 64 lakh cases are yet to be settled under the Ayushman Bharat scheme. Besides, the IMA and other representative bodies say the prices of various procedures and medical packages under the scheme are too low to be viable; they want these prices to be hiked.
Mint
6 days ago
- Mint
Acko ramps up health insurance play to expand healthcare reach
BENGALURU : Nearly a year after acquiring Better Capital-backed chronic-care startup OneCare, insurtech Acko Technology and Services Pvt. Ltd is doubling down on health insurance offerings, expanding partnerships with hospitals and clinics to tap into the growing opportunity in the space, a top executive told Mint. The Bengaluru-based unicorn acquired the digital chronic-care management company in an all-cash deal in 2024 to enter the health insurance segment. The firm, which began with auto insurance in 2016, is now working on integrating the entire process of buying health insurance—from picking a lab for medical testing to interacting with a hospital for claims. 'The problem in the health insurance industry today is that the burden of the entire process is on the customer. If there's a breakdown in the system, they're on their own. We're working towards integrating the entire system on our app and actually hand-holding customers to pick the best testing labs and hospitals," Animesh Das, managing director and chief executive of Acko General Insurance, told Mint in an interview. Acko aims to capitalize on the booming Indian healthcare sector, which is valued at over $372 billion and is growing at a compound annual growth rate of 21% since 2014, according to estimates by government think tank Niti Aayog. With health premiums already accounting for more than half of Acko's overall premium income, the firm has invested substantially to grow the segment over the last year, Das said. Acko has secured nearly $450 million in funding from investors, including Multiples PE, Accel, Elevation Capital, and General Atlantic. It was last valued at $1.1 billion in October 2021. Last week, cricketer M.S. Dhoni announced his investment in the firm and hopped on board as its brand ambassador. In the healthcare sector, Acko is in direct competition with players such as PharmEasy, HealthQuad-backed HealthifyMe, and HealthPlix that provide healthcare services such as diagnostic tests and doctor consultations. Motor insurance slowdown While Acko is yet to officially file its 2024-25 financials with the Registrar of Companies (RoC), it witnessed 'measured growth" during the year. 'It was a year of learning to know what levers will drive growth for us. Doubling down on health is a product of that learning," Das said. 'Healthcare services are a long-term game for us." The integration of its various insurance services will also result in customers engaging with the platform more regularly, which otherwise tends to be an annual activity. In the fiscal year ended March 2024, Acko's revenue climbed to ₹2,106 crore from ₹1,758 crore in the year prior, filings available with the RoC showed. Its losses narrowed marginally to ₹670 crore from ₹738 crore. Acko is among venture capital firm Elevation Capital's portfolio companies looking to get publicly listed soon. Mint reported on 6 August that the VC firm plans to take at least nine portfolio companies public over the next 12-24 months, as it gears up to monetize its portfolio amid improving public market conditions for tech and consumer startups in the country. Das declined to comment on the IPO timeline. Acko is evolving its model to keep up with a slowdown in the industry. The firm has struck a partnership with American carmaker Tesla Inc. as the insurance partner in India. 'Tesla's branding of a new-age automaker designed for young and aspirational buyers ties in well with the shift in consumer cohorts in our insurance products," Das said. A July Nuvama report said the insurance industry in India is slowing primarily due to moderation in auto sales and a drop in corporate renewal policies. Motor insurance growth has slowed down due to weak retail motor sales. The gross direct premium income (GDPI) in the motor segment rose 6.7% in June 2025, compared to 8.2% in the year-ago period.
